Quantinno Capital Management LP Buys 10,753 Shares of DaVita Inc. (NYSE:DVA)

Quantinno Capital Management LP increased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 61.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,147 shares of the company's stock after purchasing an additional 10,753 shares during the period. Quantinno Capital Management LP's holdings in DaVita were worth $4,209,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of DVA. Invesco Ltd. raised its position in DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after buying an additional 275,284 shares during the last quarter. Northern Trust Corp raised its position in DaVita by 12.5% in the 4th quarter. Northern Trust Corp now owns 740,774 shares of the company's stock valued at $110,783,000 after buying an additional 82,326 shares during the last quarter. Amundi raised its position in DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the last quarter. Deutsche Bank AG raised its position in DaVita by 35.2% in the 4th quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock valued at $58,687,000 after buying an additional 102,230 shares during the last quarter. Finally, Epoch Investment Partners Inc. acquired a new stake in DaVita in the 4th quarter valued at approximately $55,100,000. Institutional investors own 90.12% of the company's stock.

DaVita Stock Performance

Shares of DVA stock traded down $0.22 during trading on Friday, reaching $138.30. 605,497 shares of the company's stock were exchanged, compared to its average volume of 826,271. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock has a market capitalization of $10.44 billion, a PE ratio of 12.88, a PEG ratio of 1.07 and a beta of 1.14. DaVita Inc. has a twelve month low of $131.76 and a twelve month high of $179.60. The firm's fifty day moving average price is $145.32 and its 200-day moving average price is $153.39.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The firm's revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.26 EPS. As a group, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DVA. Cowen reaffirmed a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. Truist Financial lowered their price target on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research report on Monday, May 19th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Finally, Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.